CooperCompanies Q3 revenue rises 6% to $1.06 billion; raises fiscal 2025 EPS guidance
CooperCompanies reported fiscal third-quarter 2025 results for the period ended July 31, 2025, with revenue up 6% to $1,060.3 million and non-GAAP diluted EPS up 15% to $1.10, while GAAP diluted EPS fell 6% to $0.49. The company raised its fiscal 2025 non-GAAP diluted EPS guidance to $4.08 to $4.12, and CEO Al White said revenues were below expectations and that the company expects improving revenue in the fourth quarter and fiscal 2026. For shareholders, the decline in GAAP earnings and charges tied to a CooperSurgical product line exit sit alongside the higher adjusted earnings outlook.
Key points
- Revenue of $1,060.3 million, up 6% year over year and up 2% organically; CooperVision revenue was $718.4 million and CooperSurgical revenue was $341.9 million.
- GAAP diluted EPS was $0.49, down from $0.52; non-GAAP diluted EPS was $1.10, up from $0.96.
- Fiscal 2025 guidance: non-GAAP diluted EPS of $4.08 to $4.12 and total revenue of $4,076 million to $4,096 million.
- Repurchased $52.1 million of common stock in the quarter, with $163.6 million of remaining program availability.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.